Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) Stock Seems Like A Good Option

view original post

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) shares, rose in value on Friday, 09/16/22, with the stock price up by 0.20% to the previous day’s close as strong demand from buyers drove the stock to $34.90.

Actively observing the price movement in the last trading, the stock closed the session at $34.83, falling within a range of $34.07 and $35.04. The value of beta (5-year monthly) was 1.04 whereas the PE ratio was 35.36 over 12-month period. Referring to stock’s 52-week performance, its high was $36.08, and the low was $24.95. On the whole, SUPN has fluctuated by 4.15% over the past month.

Lithium Stocks In The Spotlight

Here’s a company — undiscovered by Wall Street and trading below $0.30 per share — which just recently uncovered 8 high-quality targets on unexplored ground, and drills will be turning later this year. Very few investors know about it yet… so the ground-floor opportunity below $0.30 won’t be around much longer. It’s a brand new breed of lithium explorer — all you need to do is click and the name and trading symbol is yours.

It’s all in the FREE report you can get here. .

Sponsored

With the market capitalization of Supernus Pharmaceuticals Inc. currently standing at about $1.84 billion, investors are eagerly awaiting this quarter’s results, scheduled for Feb 23, 2022 – Feb 28, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.29, which is expected to increase to $0.48 for fiscal year $1.47 and then to about $0.79 by fiscal year 2023. Data indicates that the EPS growth is expected to be 50.00% in 2023, while the next year’s EPS growth is forecast to be -46.30%.

Analysts have estimated the company’s revenue for the quarter at $164.23 million, with a low estimate of $160 million and a high estimate of $167.3 million. According to the average forecast, sales growth in current quarter could jump up 16.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $673.56 million, representing an increase of 16.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that SUPN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 50% Buy.

3 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 2 recommend it as a Buy and 0 called the SUPN stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 20.92, with the price of SUPN currently trading nearly 0.94% and 7.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 59.76, while the 7-day volatility ratio is showing 2.67% which for the 30-day chart, stands at 2.93%. Furthermore, Supernus Pharmaceuticals Inc. (SUPN)’s beta value is 1.02, and its average true range (ATR) is 1.04. The company’s stock has been forecasted to trade at an average price of $36.00 over the course of the next 52 weeks, with a low of $30.00 and a high of $40.00. Based on these price targets, the low is 14.04% off current price, whereas the price has to move -14.61% to reach the yearly target high. Additionally, analysts’ median price of $38.00 is likely to be welcomed by investors because it represents a decrease of -8.88% from the current levels.

A comparison of Supernus Pharmaceuticals Inc. (SUPN) with its peers suggests the former has fared considerably weaker in the market. SUPN showed an intraday change of 0.20% in last session, and over the past year, it grew by 28.36%%. In comparison, Eli Lilly and Company (LLY) has moved lower at -0.19% on the day and was up 33.70% over the past 12 months. On the other hand, the price of Johnson & Johnson (JNJ) has risen 1.53% on the day. The stock, however, is off 1.44% from where it was a year ago. Additionally, there is a loss of -0.36% for Bristol-Myers Squibb Company (BMY) in last trading while the stock has seen an overall depriciation of 16.81%% over the past year. The PE ratio stands at 35.36 for Supernus Pharmaceuticals Inc., compared to 49.29 for Eli Lilly and Company, and 24.36 for Johnson & Johnson. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.72%. Meanwhile, the Dow Jones Industrial Slipped by -0.45%.

Data on historical trading for Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) indicates that the trading volumes over the past 10 days have averaged 0.36 million and over the past 3 months, they’ve averaged 365.08K. According to company’s latest data on outstanding shares, there are 53.43 million shares outstanding.

The data on short interest also indicates that stock shorts accounted for 5.63 million shares as on Jul 14, 2022, resulting in a short ratio of 17.95. According to the data, the short interest in Supernus Pharmaceuticals Inc. (SUPN) stood at 10.54% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 5.51 million. The stock has risen by 19.68% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SUPN stock heading into the next quarter.